Is a legacy effect possible in IgA nephropathy?

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1657-1662

  Coppo, Rosanna ^a  

^a University Hospital   (Italy)

Author keywords

IgA Nephropathy; Legacy Effect; Long termRemission; Regression; Therapy

Indexed keywords

AZATHIOPRINE; BUDESONIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HEPARIN; IMMUNOGLOBULIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; WARFARIN;

ALBUMINURIA; DISEASE COURSE; DRUG EFFECT; EARLY INTERVENTION; GLOMERULOPATHY; GLYCEMIC CONTROL; HUMAN; IMMUNE SYSTEM; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOREGULATION; LEGACY EFFECT; MUCOSAL IMMUNITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TONSILLECTOMY; TREATMENT OUTCOME;

IGA NEPHROPATHY; LEGACY EFFECT; LONG-TERMREMISSION; REGRESSION; THERAPY;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS;

EID: 84884509036     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft016     Document Type: Review

References (60)

1. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008; 359: 1618
2. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653
3. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
4. Holman RR, Paul SK, Bethel MA et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576
5. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
6. Macisaac RJ, Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Heart Lung Circ 2011; 20: 647-654
7. Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther 2012; 14: S68-S74
8. Polanco N, Gutiérrez E, Rivera F et al., Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. Nephrol Dial Transplant 2012; 27: 231-234
9. Gbadegesin R, Lavin P, Foreman J et al. Pathogenesis and therapy of focal segmental glomerulosclerosis: an update. Pediatr Nephrol 2011; 26: 1001-1015
10. Han SH, Kang EW, Park JK et al. Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy. Nephrol Dial Transplant 2011; 26: 1570-1575
11. Davin JC. Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol 2011; 6: 679-689
12. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005; 18: 503-512
13. Bartosik LP, Lajoie G, Sugar L et al. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735
14. Reich HN, Troyanov S, Scholey JW et al. Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18: 3177-3183
15. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient. Kidney Int 2012; 82: 840-856
16. Cattran DC, Coppo R, Cook HT et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545
17. Herzenberg AM, Fogo AB, Reich HN et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011; 80: 310-317
18. Yoshikawa N, Ito H, Sakai T et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 1999; 10: 101-109
19. Kamei K, Nakanishi K, Ito S et al. Japanese Pediatric IgA Nephropathy Treatment Study Group. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 2011; 6: 1301-1307
20. Shima Y, Nakanishi K, Kamei K et al. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant 2011; 26: 163-169
21. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353: 883-887
22. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-163
23. Tang S, Leung JC, Chan LY et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802-812
24. Tang SC, Tang AW, Wong SS et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010; 7: 543-549
25. Gutiérrez E, Zamora I, Ballarín JA et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012; 23: 1753-1760
26. Coppo R, Amore A, Peruzzi L et al. Innate immunity and IgA nephropathy. J Nephrol 2010; 23: 626-632
27. Russell MW, Mestecky J, Julian BA et al. Detection of antigenic substances in patients with IgA nephropathy. J Clin Immunol 1986; 6: 74-86
28. Tomino Y, Sakai H, Miura M et al. IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. Contrib Nephrol 1984; 40: 69-73
29. Buck KS, Smith AC, Molyneux K et al. B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. Kidney Int 2008; 73: 1128-1136
30. Suzuki H, Moldoveanu Z, Hall S et al. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1. Contrib Nephrol 2007; 157: 129-133
31. Reid S, Cawthon PM, Craig JC et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011: 16:CD003962
32. Coppo R. Can a dysregulated mucosal immune system in IgA nephropathy be controlled by tonsillectomy? Nephrol Dial Transplant 2010; 25: 2395-2397
33. Wang Y, Chen J, Wang Y et al. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant 2011; 26: 1923-1931
34. Komatsu H, Fujimoto S, Hara S et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol 2008; 3: 1301-1307
35. Maeda I, Hayashi T, Sato KK et al. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transplant 2012; 27: 2806-2813
36. Kawaguchi T, Ieiri N, Yamazaki S et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria andminimal proteinuria. Nephrology (Carlton) 2010; 15: 116-123
37. Weisz-Carrington P, Grimes SR, Jr, Lamm ME. Gut-associated lymphoid tissue as source of an IgA immune response in respiratory tissues after oral immunization and intrabronchial challenge. Cell Immunol 1987; 106: 132-138
38. Emancipator SN, Gallo GR, Lamm ME. Experimental IgA nephropathy induced by oral immunization. J Exp Med 1983; 157: 572-582
39. Coppo R, Mazzucco G, Martina G et al. Gluten-induced experimental IgA glomerulopathy. Lab Invest 1989; 60: 499-506
40. Davin JC, Forget P, Mahieu PR. Increased intestinal permeability to (51 Cr) EDTA is correlated with IgA immune complex-plasma levels in children with IgA-associated nephropathies. Acta Paediatr Scand 1988; 77: 118-124
41. Nagy J, Scott H, Brandtzaeg P. Antibodies to dietary antigens in IgA nephropathy. Clin Nephrol 1988; 29: 275-279
42. Coppo R, Roccatello D, Amore A et al. Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol 1990; 33: 72-86
43. Smerud H, Fellström B, Hällgren R et al. Gastrointestinal sensitivity to soy and milk proteins in patients with IgA nephropathy. Clin Nephrol 2010; 74: 364-371
44. Wang J, Anders RA, Wu Q et al. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest 2004; 113: 826-835
45. Coppo R, Camilla R, Amore A et al. Toll-like receptor 4 expression is increased in circulating mononuclear cells of patients with immunoglobulin A nephropathy. Clin Exp Immunol 2010; 159: 73-81
46. Qin W, Zhong X, Fan JM et al. External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial Transplant 2008; 23: 1608-1614
47. Smerud HK, Bárány P, Lindström K et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 2011; 26: 3237-3242
48. Rieu P, Noël LH. Henoch-Schönlein nephritis in children and adults. Morphological features and clinicopathological correlations. Ann Med Interne 1999; 150: 151-159
49. Appel D, Kershaw DB, Smeets B et al. Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 2009; 20: 333-343
50. Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev Immunol 2012; 12: 157-167
51. Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol 2012; 40: 186-204
52. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol 2012; 3: 51
53. Fallarino F, Grohmann U. Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr Med Chem 2011; 18: 2215-2221
54. Lin FJ, Jiang GR, Shan JP et al. Imbalance of regulatory T cells to Th17 cells in IgA nephropathy. Scand J Clin Lab Invest 2012; 72: 221-229
55. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157-63.
56. Holman RR, Paul SK, Bethe MA et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359: 1565-76
57. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10- Year follow up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89
58. Jha V, Ganguli A, Saha TK et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18:1899-904.
59. Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant. 2011;11:1645-9.
60. Berthoux F, Suzuki H, Thibaudin L et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012;23:1579-87